Scienture Holdings, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Scienture Holdings, Inc. is seeking shareholder approval for critical proposals including a reverse stock split to maintain Nasdaq listing, a significant increase in authorized shares, and a potential future capital raise of up to $500 million.
NASDAQ
DEFA14A: Scienture Holdings Corrects Administrative Errors in Proxy Materials for 2024 Annual Meeting
Scienture Holdings issues a proxy supplement to correct errors in the original notice and proxy statement, clarifying that the upcoming meeting on March 10, 2025, is the 2024 annual meeting.
NASDAQ
Scienture Holdings has announced its 2025 annual meeting of stockholders to be held virtually on March 10, 2025, with several key proposals up for vote.
NASDAQ
DEF 14C: Scienture Holdings Stockholders Approve Issuance of Common Stock to Arena Investors and Arena Global
Scienture Holdings' stockholders have approved the issuance of common stock exceeding 20% of outstanding shares to Arena Investors and Arena Global, complying with Nasdaq Listing Rule 5635(d).
NASDAQ
TRxADE Health, Inc. will change its name to Scienture Holdings, Inc. after completing its merger with Scienture, Inc., a specialty pharmaceutical company.